COVID-19 (coronavirus disease 2019) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019 novel coronavirus (2019-nCoV), a strain of coronavirus. The first cases were seen in Wuhan, China in December 2019 before spreading globally. The current outbreak was recognized as a pandemic on 11 March 2020.
The non-specific imaging findings are most commonly of atypical or organizing pneumonia, often with a bilateral, peripheral, and basal predominant distribution. No effective treatment or vaccine exists currently (March 2020).
The Corona virus pandemic has costed a lot of lives through out the world.
Here are some in formations about what is known so far.
It includes cause, Spread, Signs and Symptoms.
it also has the ongoing myths about corona virus.
Its a small presentation about corona virus. Hope you will get an idea about it. Its not detail its just to give an overview of the virus and its mode of transmission. Preventive measures are also discussed.
The Corona virus pandemic has costed a lot of lives through out the world.
Here are some in formations about what is known so far.
It includes cause, Spread, Signs and Symptoms.
it also has the ongoing myths about corona virus.
Its a small presentation about corona virus. Hope you will get an idea about it. Its not detail its just to give an overview of the virus and its mode of transmission. Preventive measures are also discussed.
In this PowerPoint presentation you can get data about every aspect of COVID-19 disease.I gave every minute important detail in short form so that you can easily get that. Coronavirus disease spread globally and WHO called it as a Pandemic Disease on March 11,2020. in India it is on stage 2,please its my request to everyone stay at Home..Don't Go outside...Government provide everything which is of daily use...Don't Panic...Stay Safe..Stay At Home...Quarantine yourself for somedays.
Novel corona virus (COVID-19) its cause, symptoms and treatmentMedical Knowledge
In this SlideShare, you can learn about the pandemic Novel Corona Virus (COVID-19) and also seek knowledge about,
1. What is Coronavirus?
2. Types of the Coronavirus.
3. Transmission of Coronavirus.
4. Prevention of Coronavirus.
5. Treatment of Coronavirus.
6. Diet in Coronavirus.
7. Symptoms of Coronavirus.
8. How Coronavirus get its name?
9. What is MERS_COVID & SARS_COVID?
To download the PowerPoint of this click below:
https://drive.google.com/open?id=1s35dGMbsaO8WT2RG8NudOBc4lF2u5JXyH0MVQWpiaXk
To view the video tutorial click below:
https://youtu.be/sKVFN250l_Q
Coronaviruses are a group of related viruses that cause diseases in mammals and birds. In humans, coronaviruses cause respiratory tract infections that can be mild, such as some cases of the common cold, and others that can be lethal, such as SARS, MERS, and COVID-19. Symptoms in other species vary: in chickens, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea. There are yet to be vaccines or antiviral drugs to prevent or treat human coronavirus infections.
this presentation is prepared with the intention to create an insight about coronavirus among the undergraduate medical students in their pre and para clinical years
Rekha Dehariya (M.Sc nursing 1st year) Bhopal Nursing College, Bhopal
Covid -19 has effected broud number of people all over the world. the health education is necessary to aware people about it.
COVID-19 : Introduction,Nomenclature,Incubation Period,Structure,Symptoms,Transmission,Flowchart,Diagnosis,Treatment,Drugs under testing,Prevention,Importance of Social Distancing,Effects in Lungs,Effects in Other organs,Replication,Severity,Stages,Comparison,Facts.
In this PowerPoint presentation you can get data about every aspect of COVID-19 disease.I gave every minute important detail in short form so that you can easily get that. Coronavirus disease spread globally and WHO called it as a Pandemic Disease on March 11,2020. in India it is on stage 2,please its my request to everyone stay at Home..Don't Go outside...Government provide everything which is of daily use...Don't Panic...Stay Safe..Stay At Home...Quarantine yourself for somedays.
Novel corona virus (COVID-19) its cause, symptoms and treatmentMedical Knowledge
In this SlideShare, you can learn about the pandemic Novel Corona Virus (COVID-19) and also seek knowledge about,
1. What is Coronavirus?
2. Types of the Coronavirus.
3. Transmission of Coronavirus.
4. Prevention of Coronavirus.
5. Treatment of Coronavirus.
6. Diet in Coronavirus.
7. Symptoms of Coronavirus.
8. How Coronavirus get its name?
9. What is MERS_COVID & SARS_COVID?
To download the PowerPoint of this click below:
https://drive.google.com/open?id=1s35dGMbsaO8WT2RG8NudOBc4lF2u5JXyH0MVQWpiaXk
To view the video tutorial click below:
https://youtu.be/sKVFN250l_Q
Coronaviruses are a group of related viruses that cause diseases in mammals and birds. In humans, coronaviruses cause respiratory tract infections that can be mild, such as some cases of the common cold, and others that can be lethal, such as SARS, MERS, and COVID-19. Symptoms in other species vary: in chickens, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea. There are yet to be vaccines or antiviral drugs to prevent or treat human coronavirus infections.
this presentation is prepared with the intention to create an insight about coronavirus among the undergraduate medical students in their pre and para clinical years
Rekha Dehariya (M.Sc nursing 1st year) Bhopal Nursing College, Bhopal
Covid -19 has effected broud number of people all over the world. the health education is necessary to aware people about it.
COVID-19 : Introduction,Nomenclature,Incubation Period,Structure,Symptoms,Transmission,Flowchart,Diagnosis,Treatment,Drugs under testing,Prevention,Importance of Social Distancing,Effects in Lungs,Effects in Other organs,Replication,Severity,Stages,Comparison,Facts.
Corona viruses are a group of RNA viruses. In late December 2019, Patients with pneumonia with unknown etiology was get admitted in health care facilities in Wuhan, China, and resulted in a pandemic disease which affected more than 200 countries and responsible for 182,989 deaths world wide. The disease is officially named as Coronavirus Disease 2019 COVID 19, by WHO on February 11, 2020 . COVID 19 is a potential zoonotic disease with low to moderate estimated 2 -5 mortality rate. Currently, there is no definite treatment for COVID 19 although some trials are under investigation. Hence, appropriate use of PPE, regular hand hygiene, Respiratory and cough etiquettes, social distancing are some key elements to prevent the spread of disease. Ms. Pabalpreet Kaur | Ms. Eenu | Ms. Pooja Jaswal | Dr. (Mrs.) Jyoti Sarin "The Outbreak of COVID-19: An Overview" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-4 , June 2020, URL: https://www.ijtsrd.com/papers/ijtsrd30859.pdf Paper Url :https://www.ijtsrd.com/medicine/nursing/30859/the-outbreak-of-covid19-an-overview/ms-pabalpreet-kaur
A Meta-Analysis of COVID-19. This meta-analysis does not provide all of the answers regarding the appropriate course of action but is intended to help provide clarity assessing many of the MEDICAL considerations at play in the current pandemic. A responsible course of action addressing this pandemic must balance out a range of interconnected Medical, Economic and Social considerations.
Coronaviruses are important human and animal pathogens. At the end of 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, in the Hubei Province of China. It is rapidly spreading, resulting in an epidemic throughout china, followed by an increasing number of cases in other countries throughout the world. In February 2020, the WHO designated the disease COVID 19, which stands for corona viruses 2019. The virus that causes COVID 19 is designated severe acute respiratory syndrome coronavirus 2 SARS COV 2 previously, it was referred to as 2019 nCoV. Anushka Bharti | Dr. Gaurav Kumar Sharma | Dr. Kaushal Kishore Chandul "COVID-19" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-6 , October 2021, URL: https://www.ijtsrd.com/papers/ijtsrd46439.pdf Paper URL : https://www.ijtsrd.com/pharmacy/pharmaceutics/46439/covid19/anushka-bharti
Coronavirus Disease-19 and Reinfections: A Review of Casesasclepiuspdfs
Since first surfacing in Wuhan, China, in December 2019, the novel coronavirus disease-2019 (COVID-19) has led to a global pandemic with confirmed cases and death bells tolling in the millions with new cases still emerging daily. Despite sharing genetic similarities to the severe acute respiratory syndrome (SARS) virus, the specific viral proteins found on the novel SARS coronavirus 2 and its structure seems to make this strain much more elusive and destructive. Based on peer-reviewed cases, there seems to be an increase in patient reinfection, but due to current testing and treatment limitations, it is yet to be determined if the new trend of reinfection is due to a persistent COVID-19 infection that involves a latent period, a recurrent infection due to the same strain of COVID-19, or a mutated strain of COVID-19. The purpose of this study is to discuss the recent reports of the development of reinfection in previously confirmed COVID-19 cases in an attempt to gain a further understanding of the mechanisms of virulence, the effects on the human immune system, and how current testing and treatment modalities are faring. While the virus seems to have a penchant for patients with existing comorbidities, newer data indicate that everyone may be susceptible to possible infection and that not all patients will present with typical respiratory symptoms, making it imperative to examine established cases of reinfection in an attempt to further help with developing drugs for treatment, vaccines, and protocols for prevention.
The whole world is under the threatens of respiratory disease caused by infections of coronavirus. The latest threat to global health is the ongoing outbreak of the respiratory disease that was recently given the name Coronavirus Disease This article trying to focus on the current outbreak of and explores the epidemiology, causes, clinical manifestation and diagnosis, and prevention and control of the novel coronavirus. The aim of this article to provide valid and reliable information and increasing awareness about the COVID 19. Sameer Pawar | Sayali Budhwant | Ketan Shinde | Ashwini Sable "COVID-19: A Scoping Review" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-3 , April 2020, URL: https://www.ijtsrd.com/papers/ijtsrd30567.pdf Paper Url :https://www.ijtsrd.com/pharmacy/other/30567/covid19-a-scoping-review/sameer-pawar
Astaxanthin is a naturally occurring carotenoid which is derived from the microalgae Haematococcuspluvialis. As well as being the most powerful antioxidant known to science, it also has potent anti-inflammatory properties. Naturalastaxanthin´s distinct advantage in comparison to other antioxidants, is its ability to span the entire lipid bilayer of the cell membrane, thus providing superior protection from the inside out. Natural astaxanthin has a strong ability to both balance and strengthen the immune system. This article reviews the current available scientific literature regarding the effect of astaxanthin from the algae Haematoccus pluvialis in Astashine capsules as a natural immune booster in covid-19 infections.
Corona virus was first identified as a cause of the common cold in 1960. Until 2002, the virus was considered a relatively simple, nonfatal virus.Over the last three decades there have been three attacks of three different coronaviruses, SARS-CoV, MERS CoV and the recent one 2019 novel coronavirus (2019-nCoV).
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
2. COVID-19 (coronavirus disease 2019) is an infectious disease caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known
as 2019 novel coronavirus (2019-nCoV), a strain of coronavirus. The first cases
were seen in Wuhan, China in December 2019 before spreading globally. The
current outbreak was recognized as a pandemic on 11 March 2020.
The non-specific imaging findings are most commonly of atypical or organizing
pneumonia, often with a bilateral, peripheral, and basal predominant distribution.
No effective treatment or vaccine exists currently (March 2020).
3. .Terminology
The World Health Organization (WHO) originally called this illness "novel
coronavirus-infected pneumonia (NCIP)" and the virus itself had been named
"2019 novel coronavirus (2019-nCoV)”.
On 11 February 2020, the WHO officially renamed the clinical condition COVID-19
(a shortening of COronaVIrus Disease-19). Coincidentally, on the same day, the
Coronavirus Study Group (CSG) of the International Committee on Taxonomy of
Viruses renamed the virus "severe acute respiratory syndrome coronavirus 2"
(SARS-CoV-2). The names of both the disease and the virus should be fully
capitalized, except for the 'o' in the viral name, which is in lowercase.
The official virus name is similar to SARS-CoV, the virus strain that caused
epidemic severe acute respiratory syndrome (SARS) in 2002-2004, potentially
causing confusion. The WHO has stated it will use "COVID-19 virus" or the "virus
that causes COVID-19" instead of its official name, SARS-CoV-2, in dealings with
the public.
4. Epidemiology
As of 27 March 2020, over 535,000 cases of COVID-19 have been confirmed worldwide, having
been diagnosed in 172 territories, in six continents according to an online virus tracker created
by the medical journal, The Lancet, and hosted by Johns Hopkins University. There are nine
countries with >10,000 confirmed cases and 27 countries with between 1000 and 10,000
confirmed cases. On 27 March 2020, the USA surpassed China as the country with the most
confirmed cases.
NB: Surveillance methods and capacity vary dramatically between countries, and there is reason
to suspect that there may be a significant number of carriers in some countries not diagnosed.
The R0 (basic reproduction number) of SARS-CoV-2 has been estimated between 2.2 and 3.28,
that is each infected individual, on average, causes between 2-3 new infections.
The incubation period for COVID-19 was initially calculated to be ~5 days, which was based on 10
patients only 12. An American group performed an epidemiological analysis of 181 cases, for
which days of exposure and symptom onset could be estimated accurately. They calculated a
median incubation period of 5.1 days,that 97.5% became symptomatic within 11.5 days (CI, 8.2 to
15.6 days) of being infected, and that extending the cohort to the 99th percentile results in almost
all cases developing symptoms in 14 days after exposure to SARS-CoV-2.
5. Epidemiology
The number of deaths from COVID-19 is over 24,000 (27 March), with a case fatality
rate of 2-3%. It is speculated that the true case fatality rate is lower than this, because
many mild cases are not being tested which thus skews the apparent death rate
upwards.
A paper published by the Chinese Center for Disease Control and Prevention (CCDC)
analyzed all 44,672 cases diagnosed up to 11 February 2020. Of these, 1.2% were
asymptomatic and 80.9% were classed as "mild".
Another study looked at clinical characteristics in COVID-19 positively tested closed
contacts of COVID-19 patients. Approximately 30% of those COVID-19 positive close
contacts never developed any symptoms or changes on chest CT scans. The
remainder showed changes on CT but ~20% reportedly developed symptoms during
their hospital course, none of them developed severe disease. This suggests that a
high percentage of COVID-19 carriers are asymptomatic.
In the Chinese population, 55-60%% of COVID-19 patients were male and the median
age has been reported between 47 and 59 years.
6. Clinical presentation
COVID-19 typically presents with systemic and/or respiratory manifestations. Some individuals
infected with SARS-CoV-2 are asymptomatic and can act as carriers. Some also experience
mild gastrointestinal or cardiovascular symptoms, although these are much less common.
The full spectrum of clinical manifestation of COVID-19 remains to be determined. Symptoms
and signs are non-specific:
Uncommon:
fever (85-90%)
cough (65-70%)
fatigue (35-40%)
sputum production (30-35%)
shortness of breath (15-20%)
7. Clinical presentation
Less common:
myalgia/arthralgia (10-15%)
headaches (10-15%)
sore throat (10-15%)
chills (10-12%)
pleuritic pain
Rare:
nausea, vomiting, nasal congestion (<10%), diarrhea (<5%)
palpitations, chest tightness
Anecdotal reports from ENT specialists in the UK suggest that COVID-19 sufferers have high
rates of anosmia/hyposmia. However, no peer-reviewed studies currently support this.
8. Diagnosis
The definitive test for SARS-CoV-2 is the real-time reverse transcriptase-
polymerase chain reaction (RT-PCR) test and is believed to be highly specific, but
with sensitivity reported as low as 60-70% 32 and as high as 95-97% 56. Thus, false
negatives are a real clinical problem and several negative tests might be required
in a single case to be confident about excluding the disease.
Multiple radiological organizations have come forward to state that CT should not
be relied upon as a primary diagnostic/screening tool for COVID-19. On 16 March
2020, an American-Singaporean panel published that CT findings were not part of
the diagnostic criteria for COVID-19. However, CT findings have been used as a
surrogate diagnostic test by some.
9. Laboratory tests
The most common ancillary laboratory findings in a study of 138 hospitalized
patients were the following:
lymphopenia
increased prothrombin time (PT)
increased lactate dehydrogenase
Mild elevations of inflammatory markers (CRP and ESR) and D-dimer are also
seen.
10. Complications
In one of the largest studies of hospitalized patients, reviewing 1,099 individuals across China, the
admission rate to the intensive care unit (ICU) was 5%. In this same study, 6% of all patients required
ventilation, whether invasive or non-invasive.
ICU patients tend to be older with more comorbidities. Common reported sequelae include the followin
acute respiratory distress syndrome (ARDS): ~22.5% (range 17-29%)
acute cardiac injury: elevated troponin levels
o myocardial ischemia
o cardiac arrest
secondary infections
sepsis
acute kidney injury (AKI)
multiorgan failure
In a small subgroup of severe ICU cases:
secondary hemophagocytic lymphohistiocytosis (a cytokine storm syndrome)
11. Etiology
On 9 January 2020, the World Health Organization (WHO) confirmed that SARS-CoV-2 was the
cause of COVID-19 (2019-nCoV was the name of the virus at that time). It is a member of
the Betacoronavirus genus, one of the genera of the Coronaviridae family of
viruses. Coronaviruses are enveloped single-stranded RNA viruses that are found in humans,
mammals and birds. These viruses are responsible for pulmonary, hepatic, CNS, and intestinal
disease. As with many human infections, SARS-CoV-2 is zoonotic. The closest animal
coronavirus by genetic sequence is a bat coronavirus, and this is the likely ultimate origin of
the virus. The disease can also be transmitted by snakes.
Six coronaviruses are known to cause human disease.Two are zoonoses: the severe acute
respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome
coronavirus (MERS-CoV), both of which may sometimes be fatal. The remaining four viruses
cause the common cold.
12. Pathophysiology
The SARS-CoV-2 virus, like the closely-related MERS and SARS coronaviruses, effects its
cellular entry via attachment of its virion spike protein (a.k.a. S protein) to the
angiotensin-converting enzyme 2 (ACE 2) receptor. This receptor is commonly found on
alveolar cells of the lung epithelium, underlying the development of respiratory
symptoms as the commonest presentation of COVID-19. It is thought that the mediation
of the less common cardiovascular effects is also via the same ACE-2 receptor which is
also commonly expressed on the cells of the cardiovascular system.
13. Transmission
Although originating from animals, COVID-19 is not considered a direct zoonosis as its transmission is
now primarily human-to-human. It is primarily transmitted in a similar way to the common cold, via
contact with droplets of infected individuals' upper respiratory tract secretions, e.g. from sneezing or
coughing.
A recent Bayesian regression model has found that aerosol and fomite transmission are plausible.
Orofecal spread was seen with the SARS epidemic, and although it remains unclear if SARS-CoV-2 can
be transmitted in this way, there is some evidence for it.
A recently published cohort study (26 March 2020) could not rule out the possibility of vertical
transmission with 9% of neonates (n=3/33) developing an early onset SARS-CoV-2 infection despite
strict infection control measures during delivery. However, a retrospective study of nine pregnant
patients infected by SARS-CoV-2 did not show any evidence of vertical/intrauterine infection. More
recent published (20 March 2020) guidance from a joint American-Chinese consensus panel stated that
it remains unclear if vertical transmission can occur.
14. Infection precautions
Given that the staff in a medical imaging department are some of the first parties to be in
contact with COVID-19 patients, clear infection control guidelines are imperative. At the time
of writing (8 March 2020) droplet-type precautions are in place for COVID-19 patients, that is,
medical mask, gown, gloves, and eye protection (aerosol-generating procedures require N95
masks and aprons).
Patients requiring general radiography should receive it portably (to limit transporting
patients) or in dedicated auxiliary units. Patients that require transport to departments must
wear a mask to and from the unit. Machines, including any ancillary equipment used during
examinations, should be cleaned after examinations. It is recommended that any imaging
examinations have two radiographers in attendance using the 'one clean, one in contact with
the patient' system to minimize cross-contamination. SARS-CoV-2 can exist on surfaces for up
to 72 hours, reinforcing the need for protection of equipment with barriers such as covers and
thorough cleaning of equipment between patients.
Please follow your departmental policies on personal protective equipment (PPE)
15. Non-urgent care
Both the American College of Radiology (ACR) and the Centers for Disease Control and
Prevention (CDC) in the United States advise that non-urgent outpatient appointments
should be rescheduled. The British Society of Skeletal Radiologists has advised that
intra-articular, soft tissue and perineural steroid injections may reduce viral immunity and
therefore should not be performed unless they are unavoidable.
CT protocol
Patients requiring CT should receive a non-contrast chest CT (unless iodinated contrast
medium is indicated), with reconstructions of the volume at 0.625-mm to 1.5-mm slice
thickness (gapless). If iodinated contrast is indicated (for example a CT pulmonary
angiogram), a non-contrast scan should be considered prior to contrast administration,
as contrast may impact the interpretation of GGO patterns
16. Radiographic features
The primary findings of COVID-19 on chest radiograph and CT are those of atypical
pneumonia or organizing pneumonia.
Imaging has limited sensitivity for COVID-19, up to 18% demonstrate normal chest x-
rays or CT when mild or early in the disease course but this decreases to 3% in severe
disease. Bilateral and/or multilobar involvement is common.
Plain radiograph
may be normal in initial stages
asymmetric patchy or diffuse airspace opacities have been descibed
17. CT
The primary findings on CT in adults have been reported:
ground-glass opacities (GGO): bilateral, subpleural, peripheral
crazy paving appearance (GGOs and inter-/intra-lobular septal thickening)
air space consolidation
bronchovascular thickening in the lesion
traction bronchiectasis
The ground-glass and/or consolidative opacities are usually bilateral, peripheral, and basal in
distribution.
A retrospective study of 112 patients found 54% of asymptomatic patients had pneumonic
changes on CT.
Some papers suggest that CT has a sensitivity that could justify its use in the early imaging in
the acute setting in select cases. Yet its use as a primary screening tool is currently
discouraged, not least because these studies tended to suffer from selection bias. In a recent
investigation, these chest CT findings had the highest discriminatory value (p<0.001):
peripheral distribution
ground-glass opacity
bronchovascular thickening (in lesions)
18. Atypical CT findings
These findings only seen in a small minority of patients should raise concern
for superadded bacterial pneumonia or other diagnoses:
mediastinal lymphadenopathy
pleural effusions: may occur as a complication of COVID-19
multiple tiny pulmonary nodules (unlike many other viral pneumonia)
tree-in-bud
pneumothorax
cavitation
19. Temporal CT changes
Four stages on CT have been described:
early/initial stage (0-4 days): normal CT or GGO only
o up to half of patients have normal CT scans within 2 days of symptom
onset
progressive stage (5-8 days): increased GGO and crazy paving
appearance.
peak stage (9-13 days): consolidation
absorption stage (> 14 days): with an improvement in the disease
course, "fibrous stripes" appear and the abnormalities resolve at 1 month
and beyond.
20. Pediatric CT
In a small study of five children that had been admitted to hospital with positive
COVID-19 RT-PCR tests and who had CT chest performed, only three children
had abnormalities. The main abnormality was bilateral patchy ground-glass
opacities, similar to the appearances in adults, but less florid, and in all three
cases the opacities resolved as they clinically recovered.
On 18 March 2020, the details of a much larger cohort of 171 children with
confirmed COVID-19, and evaluated in a hospital setting was published as a letter
in the New England Journal of Medicine. Ground-glass opacities were seen in
one-third of the total, whereas almost 16% of children had no imaging features of
pneumonia.
21. Ultrasound
Initial work on patients in China suggests that lung ultrasound may be useful in the evaluation of
critically ill COVID-19 patients. The following patterns have been observed, tending to have a
bilateral and posterobasal predominance:
multiple B-lines
o ranging from focal to diffuse with spared areas
o representative of thickened subpleural interlobular septa
irregular, thickened pleural line with scattered discontinuities
subpleural consolidations
o can be associated with a discrete, localized pleural effusion
o relatively avascular with color flow Doppler interrogation
o pneumonic consolidation typically associated with preservation of flow or hyperemia
alveolar consolidation
o tissue-like appearance with dynamic and static air bronchograms
o associated with severe, progressive disease
restitution of aeration during recovery
reappearance of bilateral A-lines
22. Treatment
No specific treatment or vaccine exists for COVID-19 (March 2020). Therefore
resources have been concentrated on public health measures to prevent further
inter-human transmission of the virus. This has required a multipronged
approach and for individuals includes meticulous personal hygiene, the
avoidance of large crowds/crowded environments and where necessary, self-
isolation.
In healthcare facilities, concerted efforts are required to effect rapid diagnosis,
quarantine infected cases and provide effective supportive therapies. This will
encompass empirical treatments with antibiotics, antivirals, and supportive
measures. Mechanical ventilation and extracorporeal membrane oxygenation
(ECMO) have also been used where clinically necessary.
23. Antiviral therapy
Whilst specific antiviral therapies for SARS-2-CoV do not currently exist, the combination of the protease
inhibitors, ritonavir, and lopinavir, or a triple combination of these antiviral agents with the addition of
ribavirin, showed some success in the treatment of SARS, and early reports suggested similar efficacy
in the treatment of COVID-19. However, a more recent randomized, controlled open-label trial failed to
demonstrate any added benefit of lopinavir-ritonavir combination therapy.
Remdesivir, a drug originally developed to treat Ebola virus and shown to be effective against MERS-CoV
and SARS-CoV, showed promising in vitro results against SARS-CoV-2 and is undergoing phase III trials.
Other antivirals in phase III trials include oseltamivir, ASC09F (HIV protease inhibitor), lopinavir,
ritonavir, darunavir, and cobicistat.
Early reports demonstrated that treatment with two antimalarial drugs, chloroquine, and its close
chemical derivative, hydroxychloroquine, have a beneficial effect on the clinical outcome, and it was also
shown that they demonstrate anti-SARS-2-CoV activity in vitro. This was further corroborated by a recent
open-label, randomized clinical trial, which demonstrated a significant reduction of viral carriage, and a
lower average carrying duration in patients treated with hydroxychloroquine. Furthermore, a
combination with the antibiotic azithromycin resulted in a synergistic effect.
24. Vaccines
The primary target in developing coronavirus vaccines has been the spike
protein (S protein) which is on the surface of the virion particle, and in vivo is
the most important antigen for triggering an immune response.
Vaccines for the coronaviruses have been under development since the SARS
outbreak, but none are yet available for humans. A phase I trial in humans of a
potential vaccine against MERS-CoV has already been performed in the UK.
25. NSAIDs
Emerging expert opinion is that non-steroidal anti-inflammatory drugs (NSAIDs) are relatively
contraindicated in those with COVID-19. This is based upon several strands of "evidence":
since 2019 the French government National Agency for the Safety of Medicines and Health
Products has advised against the routine use of NSAIDs as antipyretic
previous research has shown that NSAIDs may suppress the immune system
anecdotal reports from France suggest that young patients on NSAIDs, otherwise previously
fit and well, developed more severe COVID-19 symptoms
However, it is important to note that there is currently (March 2020) no published scientific
evidence showing that NSAIDs increase the risk of developing COVID-19 or worsen established
disease. Also, at least one report shows antiviral activity by indomethacin (an NSAID) against
SARS-CoV (cause of SARS).
26. Prognosis
Progressive deterioration of imaging changes despite medical treatment is thought
to be associated with poor prognosis. There is an increased risk of death in men
over the age of 60 years old. The mortality rate is estimated to be 3.6%.
Early reports show that in some well patients, the RT-PCR test remains falsely
positive despite an apparent clinical recovery. This raises the concern that
asymptomatic carriage may occur.
27. History and etymology
The first mention in the medical press about the emerging infection was in the British
Medical Journal (BMJ) on 8 January 2020 in a news article, which reported "outbreak of
pneumonia of unknown cause in Wuhan, China, has prompted authorities in neighboring
Hong Kong, Macau, and Taiwan to step up border surveillance, amid fears that it could signal
the emergence of a new and serious threat to public health". The first scientific article about
the new disease, initially termed 2019‐new coronavirus (2019‐nCoV) by the World Health
Organization (WHO), was published in the Journal of Medical Virology on 16 January 2020.
28. History and etymology
On 13 January 2020, the first confirmed case outside China was diagnosed, a Chinese
tourist in Thailand. On 20 January, the first infected person in the United States was
confirmed to be a man who had recently returned from Wuhan. The infection was declared
a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 by the
WHO. On 28 February 2020, the WHO increased the global risk assessment of COVID-19 to
“very high” which is the highest level. On 11 March 2020, COVID-19 was declared a
pandemic by the WHO.
The WHO originally called this illness "novel coronavirus-infected pneumonia (NCIP)" and
the virus itself had been named "2019 novel coronavirus (2019-nCoV)" 1. On 11 February
2020, the WHO officially renamed the clinical condition COVID-19 (a shortening of
CoronaVirus Disease-19). On the same day, the Coronavirus Study Group (CSG) of the
International Committee on Taxonomy of Viruses renamed the virus "severe acute
respiratory syndrome coronavirus 2" (SARS-CoV-2).
29. Differential diagnoses
viral pneumonia including:
o influenza pneumonia A and B
distribution more along the bronchovascular bundles
bronchial wall thickening
o paramyxovirus pneumonia
o cytomegalovirus (CMV) pneumonia
o adenovirus pneumonia
o SARS-CoV pneumonia
o MERS coronavirus
o HSV pneumonia
in immunocompromised patients
often shows pleural effusions
o respiratory syncytial virus (RSV) pneumonia
atypical bacterial pneumonia
o mycoplasma pneumonia
mainly children and adolescents
bronchial wall thickening
centrilobular nodules
o chlamydia pneumonia
pulmonary edema
interstitial lung disease
o cryptogenic organizing pneumonia
o chronic eosinophilic pneumonia (CEP)